Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on August 29, 2017, by Lexaria Bioscience Corp., a Nevada corporation. The report details unregistered sales of equity securities and Regulation FD disclosures regarding upcoming industry conferences and debt settlements.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. Specific transactional values reported include:
- Debt Extinguished: $45,000 (convertible debt plus interest) and $12,000 (director debt).
- Shares Issued: 307,500 restricted common shares and 32,433 common shares.
- Conversion Prices: US$0.15 per share for the convertible debt and US$0.37 per share for the director debt settlement.
Material Changes
The primary material changes involve the reduction of debt obligations through the issuance of equity:
- Execution of a notice of conversion extinguishing $45,000 of convertible debt plus interest in exchange for 307,500 shares.
- Issuance of 32,433 shares to settle $12,000 of debt owed to a director.
Outlook, Commentary, and Risks
Management Commentary and Events: CEO Chris Bunka is scheduled to present on cannabis industry technology at the Investorshub International Cannabis Conference in Los Angeles (September 1-2) and the Institutional Capital & Cannabis Conference in Miami Beach (September 7-8).
Risks and Contingencies: The securities issued in these transactions were not registered under the Securities Act of 1933. They may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-issuance (307,500 + 32,433 new shares).
- Confirm the remaining balance of convertible debt and other liabilities following these settlements.
- Review the specific terms of the exemptions used for the unregistered share issuances.
- Assess the impact of the share issuances on existing shareholder dilution.